UBS keeps GSK at 'neutral' with focus on chief executive's strategy update

UBS says investors will pay limited attention to GSK’s Q2 results, with focus shifting to CEO Luke Miels’ strategy update and a capital markets day on 28 July. The bank reiterated a “neutral” rating on GSK ahead of the results and the upcoming event.

Analysis

UBS says investors will pay limited attention to GSK’s Q2 results, with focus shifting to CEO Luke Miels’ strategy update and a capital markets day on 28 July. The bank reiterated a “neutral” rating on GSK ahead of the results and the upcoming event.